Thursday, March 23, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosurveillance

CDC Expands Airport COVID-19 Biosurveillance Project with XpresCheck

by Global Biodefense Staff
January 31, 2022
CDC Expands Airport COVID-19 Biosurveillance Project with XpresCheck

Airport COVID screening. Credit: Ryan Campbell

XpresSpa Group, Inc. has announced the extension of their initial $2 million airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary XpresCheck®, bringing the total contract to $5.6 million.

First launched in September 2021, the COVID-19 biosurveillance program consisted of an 8-week pilot that focuses on the importation of emerging SARS-CoV-2 variants in the United States on flights originating from India.

“During the Thanksgiving holiday, we worked closely with the CDC to pivot and expand our surveillance program to screen for the new, highly contagious Omicron variant that was identified just days earlier in Africa,” said Ezra Ernst, XpresCheck’s recently appointed chief executive officer. “Together, with our testing partner, Concentric by Ginkgo, we successfully expanded the program to monitor additional flights from around the globe.”

With the recent expansion, the program now tests passengers entering the United States from seven African countries, including passengers making connections through the United Kingdom, France, Germany and Brazil – countries that have been identified as Level 4 Risk Assessment for COVID-19. Initially, the biosurveillance program provided testing for travelers arriving from India at three key United States airports including John F. Kennedy International Airport, Newark-Liberty International Airport and San Francisco International Airport. The expansion also included the addition of Hartsfield-Jackson Atlanta International Airport, bringing the number of testing sites to four.

“For the past 3 months, XpresCheck and their testing partner, Concentric by Gingko, demonstrated that a traveler-based SARS-CoV-2 viral genomic surveillance program can help detect emerging SARS-CoV-2 variants in the United States,” said Dr. Cindy R. Friedman, chief of CDC’s Travelers’ Health Branch. “In fact, following the rapid expansion over the Thanksgiving break, the program detected the first documented U.S. cases of Omicron sub-lineage BA.2 and BA.3,” added Friedman.

Operationally, the current expansion utilizes the same tests and processes as the pilot program. Passengers take a PCR test, which is combined with 5-10 other samples and sent to the lab to determine the presence of COVID-19. If the presence of COVID-19 is detected in the pooled sample, the viral samples will undergo genomic sequencing to identify the presence of any variants, such as the Omicron variant. In addition to the pooled tests, participating travelers are provided a free take-home PCR test which they are recommended to take within 3-5 days after their arrival. Both tests help the CDC understand which variants are making their way to the U.S.

Tags: COVID-19Editor PickTravel Restrictions

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Why Do Some of the Outbreak Genomes Have More Mutations Than Others?
Biosurveillance

Virginia Institutes Partner to Join National Pathogen Genomics Centers of Excellence Network

October 25, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy